News >

Navigating Frontline Therapy and Treatment Beyond Progression in NSCLC

Caroline Seymour
Published: Tuesday, May 21, 2019

Bing Xia, MD

Bing Xia, MD

Results of the phase III KEYNOTE-189 and IMpower150 trials showed a profound survival benefit in patients with advanced nonsquamous non–small cell lung cancer (NSCLC), when pembrolizumab (Keytruda) and atezolizumab (Tecentriq), respectively, were added to standard chemotherapeutic backbones. Now, selection between the 2 regimens must be based on individual risk factors and comorbidities, explained Bing Xia, MD.

In KEYNOTE-189, patients who received the combination of pembrolizumab, pemetrexed, and platinum-based chemotherapy experienced a 51% reduction in the risk of death compared with those who received chemotherapy alone.1 In IMpower150, the regimen of atezolizumab, carboplatin, paclitaxel, and bevacizumab (Avastin) led to a 22% reduction in the risk of death versus those who received chemotherapy and bevacizumab alone.2

“Now we know that patients do better when we combine chemotherapy and immunotherapy,” said Xia. “If you have a healthy patient with no contraindications to immunotherapy, try the combination upfront.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication